Twenty five patients did not receive chemotherapy: 19/25 (76%) had stage I disease of whom 16 are alive and three are lost to follow-up, presumed alive. Three had stage II disease of whom two died of disease and one is a survivor. Two had stage III disease and one stage IV disease; all of whom died.  Chemotherapy was administered to 192 patients: 88 (45.8%) patients received JEb, 85 (44.2%) BEP, seven (3.6%) PEb and 12 (6.3%) a variety of non-standard regimens with a mean of 4.7 courses (range 1-11 courses). One hundred medical treatment-related events occurred in 61 patients (Supplemental TABLE S1), the most predictable acute effects being cytopaenias (24) and febrile neutropaenia (11) with hearing loss (19) the commonest subacute/late effect.